scholarly journals Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1973
Author(s):  
David Blánquez-Martínez ◽  
Xando Díaz-Villamarín ◽  
Alba Antúnez-Rodríguez ◽  
Ana Pozo-Agundo ◽  
José Ignacio Muñoz-Ávila ◽  
...  
Keyword(s):  
Genetic Polymorphisms ◽  
Genetic Variants ◽  
High Myopia ◽  
Antibody Fragment ◽  
The United States ◽  
Vascular Endothelial ◽  
Humanized Monoclonal Antibody ◽  
Ophthalmic Pathology ◽  
Endothelial Growth Factor ◽  
Vegfa Gene

High myopia is an ophthalmic pathology that affects half of the young adults in the United States and Europe and it is predicted that a third of the world’s population could be nearsighted at the end of this decade. It is characterized by at least 6 diopters or axial length > 26 mm and, choroidal neovascularization (CNV) in 5 to 11% of cases. Ranibizumab is a recombinant humanized monoclonal antibody fragment. It is an anti-vascular endothelial growth factor (anti-VEGF) drug used in the treatment of CNV. Many genetic polymorphisms have been associated with interindividual differences in the response to ranibizumab, but these associations were not yet assessed among patients with high myopia and CNV. We performed a retrospective study assessing the association of genetic polymorphisms with response to ranibizumab in patients with CNV secondary to high myopia (mCNV). We included genetic polymorphisms previously associated with the response to drugs used in CNV patients (bevacizumab, ranibizumab, aflibercept, and photodynamic therapy (PDT)). We also included genetic variants in the VEGFA gene. Based on our results, ARMS2 (rs10490924) and CFH (rs1061170) are associated with response to ranibizumab in high myopia patients; and, included VEGFA genetic polymorphisms are not associated with ranibizumab response in our population but might be related to a higher risk of CNV.

scholarly journals Myopic foveal detachment associated with pachychoroid characteristics

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yong Kyun Shin ◽  
Sun Hyup Han ◽  
Se Woong Kang ◽  
Sang Jin Kim ◽  
A Young Kim
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Multimodal Imaging ◽  
High Myopia ◽  
Complete Response ◽  
Response To Treatment ◽  
Vascular Endothelial ◽  
Foveal Detachment ◽  
Endothelial Growth Factor ◽  
Choroidal Vascular Hyperpermeability

Abstract Purpose To describe myopic nontractional foveal detachment associated with pachychoroid diseases. Methods This retrospective study included 15 myopic eyes which had nontractional serous foveal detachment. The eyes were divided into myopic central serous chorioretinopathy (CSC) group (n = 8) and a myopic pachychoroid neovascularization (PNV) group (n = 7) according to the presence of type 1 choroidal neovascularization on multimodal imaging. The findings of multimodal imaging and treatment response were described. Results In myopic CSC group, pachychoroid features such as pachyvessels, choroidal vascular hyperpermeability and punctate hyperfluorescent spots were noted in 8 eyes (100%), 8 eyes (100%), 5 eyes (62.5%) respectively. The above features were noted in 7 eyes (100%), 5 eyes (83.3%), 5 eyes (83.3%), respectively, in the myopic PNV group. Five of 8 eyes in myopic CSC and all 7 eyes received treatment including anti-vascular endothelial growth factor injection and/or photodynamic therapy. However, only five eyes had a complete response. Conclusions The pachychoroid phenotype may coexist with high myopia and lead to myopic nontractional serous foveal detachment. Our series suggest that the response to treatment for these conditions would be limited.

scholarly journals Organic Nanocarriers for Bevacizumab Delivery: An Overview of Development, Characterization and Applications

Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4127
Author(s):  
Aline de Cristo Soares Alves ◽  
Franciele Aline Bruinsmann ◽  
Silvia Stanisçuaski Guterres ◽  
Adriana Raffin Pohlmann
Keyword(s):  
Monoclonal Antibody ◽  
Physicochemical Characterization ◽  
Vascular Endothelial ◽  
Organic Nanoparticles ◽  
Humanized Monoclonal Antibody ◽  
Angiogenesis Process ◽  
Endothelial Growth Factor ◽  
Drug Pharmacokinetics

Bevacizumab (BCZ) is a recombinant humanized monoclonal antibody against the vascular endothelial growth factor, which is involved in the angiogenesis process. Pathologic angiogenesis is observed in several diseases including ophthalmic disorders and cancer. The multiple administrations of BCZ can cause adverse effects. In this way, the development of controlled release systems for BCZ delivery can promote the modification of drug pharmacokinetics and, consequently, decrease the dose, toxicity, and cost due to improved efficacy. This review highlights BCZ formulated in organic nanoparticles providing an overview of the physicochemical characterization and in vitro and in vivo biological evaluations. Moreover, the main advantages and limitations of the different approaches are discussed. Despite difficulties in working with antibodies, those nanocarriers provided advantages in BCZ protection against degradation guaranteeing bioactivity maintenance.

scholarly journals Vascular Endothelial Growth Factor Inhibitor-Induced Hypertension: Basics for Primary Care Providers

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Carmen P. Escalante ◽  
Ali Zalpour
Keyword(s):  
Primary Care ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Drug Class ◽  
Primary Care Providers ◽  
The United States ◽  
Vascular Endothelial ◽  
Care Providers ◽  
Vegf Inhibitors ◽  
Endothelial Growth Factor

Frequently, primary care providers continue to manage the overall medical care of cancer patients. With newer and often more potent antitumor agents, patients may present to their local physicians with drug-induced toxicities such as hypertension induced by vascular endothelial growth factor (VEGF) inhibitors. It is imperative that these healthcare providers are aware of basic aspects of this drug class, as its use has increased significantly in the last several years. Uncontrolled or malignant hypertension due to these agents should be recognized readily and treated early to prevent more severe outcomes. This overview provides a brief background on the role of VEGF and angiogenesis in tumor metabolism as well as theories of the mechanism of VEGF inhibitors and hypertension. Helpful clinical practice aspects including the types of inhibitors used in the United States and their pharmacologic characteristics will be discussed. Also, diagnosis and treatment of hypertension induced by vascular endothelial growth factors are reviewed. A summary of key aspects of this drug class and hypertension is included.

Sign in / Sign up

Export Citation Format

Share Document